Suppr超能文献

术后未重新使用血管紧张素转换酶抑制剂与 30 天死亡率风险相关:退伍军人事务医疗保健系统的回顾性研究。

Thirty-day mortality risk associated with the postoperative nonresumption of angiotensin-converting enzyme inhibitors: a retrospective study of the Veterans Affairs Healthcare System.

机构信息

Anesthesia Service, Veterans Affairs Palo Alto Health Care System, Palo Alto and Department of Anesthesiology, Perioperative, and Pain Medicine, Stanford University, Stanford, California.

出版信息

J Hosp Med. 2014 May;9(5):289-96. doi: 10.1002/jhm.2182.

Abstract

BACKGROUND

Angiotensin-converting enzyme inhibitors (ACE-Is) are a widely used class of cardiovascular medication. However, limited data exist on the risks of postoperative nonresumption of an ACE-I.

OBJECTIVE

To evaluate the factors and 30-day mortality risks associated with the postoperative nonresumption of an ACE-I.

DESIGN

A retrospective cohort study.

SETTING

Veterans Affairs (VA) Healthcare System.

PATIENTS

A total of 294,505 admissions in 240,978 patients with multiple preoperative prescription refills (>3) for an ACE-I who underwent inpatient surgery from calendar years 1999 to 2012.

INTERVENTION

None.

MEASUREMENTS

We classified surgical admissions based upon the timing of postoperative resumption of an ACE-I prescription from the day of surgery through postoperative days 0 to 14 and 15 to 30, and collected 30-day mortality data. We evaluated the relationship between 30-day mortality and the nonresumption of an ACE-I from postoperative day 0 to 14 using proportional hazard regression models, adjusting for patient- and hospital-level risk factors. Sensitivity analyses were conducted using more homogeneous subpopulations and propensity score models.

RESULTS

Twenty-five percent of our cohort did not resume an ACE-I during the 14 days following surgery. Nonresumption of an ACE-I within postoperative day 0 to 14 was independently associated with increased 30-day mortality (hazard ratio: 3.44; 95% confidence interval: 3.30-3.60; P < 0.001) compared to the restart group. Sensitivity analyses maintained this relationship.

CONCLUSIONS

Nonresumption of an ACE-I is common after major inpatient surgery in the large VA Health Care System. Restarting of an ACE-I within postoperative day 0 to 14 is, however, associated with decreased 30-day mortality. Careful attention to the issue of timely reinstitution of chronic medications such as an ACE-I is indicated.

摘要

背景

血管紧张素转换酶抑制剂(ACE-Is)是一类广泛使用的心血管药物。然而,关于术后不继续使用 ACE-I 的风险的数据有限。

目的

评估与术后不继续使用 ACE-I 相关的因素和 30 天死亡率风险。

设计

回顾性队列研究。

设置

退伍军人事务部(VA)医疗保健系统。

患者

1999 年至 2012 年期间,共有 240978 名患者在 294505 次住院期间接受了多次术前处方(>3 次)ACE-I 药物治疗,进行了住院手术。

干预

无。

测量

我们根据术后 ACE-I 处方恢复的时间,将手术入院分为从手术日起至术后第 0 至 14 天和第 15 至 30 天,并收集了 30 天死亡率数据。我们使用比例风险回归模型评估了术后第 0 至 14 天不继续使用 ACE-I 与 30 天死亡率之间的关系,调整了患者和医院水平的风险因素。使用更同质的亚人群和倾向评分模型进行了敏感性分析。

结果

我们队列的 25%在术后 14 天内没有继续使用 ACE-I。与重新开始组相比,术后第 0 至 14 天内不继续使用 ACE-I 与 30 天死亡率增加独立相关(危险比:3.44;95%置信区间:3.30-3.60;P<0.001)。敏感性分析维持了这种关系。

结论

在大型退伍军人事务部医疗保健系统中,大型住院手术后不继续使用 ACE-I 很常见。然而,在术后第 0 至 14 天内重新开始使用 ACE-I 与 30 天死亡率降低相关。需要谨慎关注 ACE-I 等慢性药物的及时重新使用问题。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验